Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 5/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | CXCR4 | P61073 | 3/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL803403 | 0.92 | KDM4E (0.36) | CYP2D6CXCR4LMNACYP1A2 | |
| SCHEMBL803399 | 0.84 | KDM4E (0.40) | CYP2D6CXCR4POLB | |
| SCHEMBL803676 | 0.83 | LMNA (0.50) | PDE2AALDH1A1LMNACYP1A2POLB | |
| SCHEMBL803401 | 0.81 | MAPT (0.49) | CYP2D6ALDH1A1LMNACYP1A2CYP3A4 | |
| SCHEMBL803467 | 0.81 | TNKS (0.38) | ALDH1A1LMNANPC1RAB9AKAT2B | |
| SCHEMBL803671 | 0.76 | KAT2B (0.46) | PDE2ACYP2D6ALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL803679 | 0.75 | KDM4E (0.53) | PDE2ACYP2D6ALDH1A1LMNACYP1A2 | |
| SCHEMBL803673 | 0.74 | CHRNB2 (0.58) | PDE2AALDH1A1POLBMAPTMEN1 | |
| SCHEMBL5962222 | 0.74 | HRH3 (0.45) | ALDH1A1CYP1A2CYP3A4KMT2A | |
| SCHEMBL803095 | 0.72 | HSD11B1 (0.47) | POLBMAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8680159-B2 | Bradykinin 1 receptor modulating compounds | GRUENENTHAL GMBH (DE) | 2014-03-25 | — | — | US | disclosed |
| US-20120071461-A1 | Substituted Benzamide Compounds | GRUENENTHAL GMBH (DE) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071461-A1 | Substituted Benzamide Compounds | BDKRB1, BDKRB2, HRH2 | PDE2A 611/4885CYP2D6 900/4885CXCR4 325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.